Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02045485 |
| Other study ID # |
901215 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
February 26, 2013 |
| Last updated |
January 22, 2014 |
| Start date |
January 2006 |
Study information
| Verified date |
January 2014 |
| Source |
Yuzuncu Yil University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Turkey: Ethics Committee |
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Background:
Several reports have demonstrated an association between psoriasis and cardiovascular
diseases. P wave dispersion (PWD) is the most important electrocardiographic (ECG) markers
used to evaluate the risk of atrial arrhythmias. QT dispersion (QTD) can be used to assess
homogeneity of cardiac repolarization and may be a risk for ventricular arrhythmias.
Aim: To search PWD and QTD in patients with psoriasis. Methods: Ninety-four outpatient
psoriasis patients and 51 healthy people were evaluated by physical examination, 12-lead ECG
and transthoracic echocardiography. Severity of the psoriasis was evaluated by psoriasis
Area and Severity Index (PASI).
Description:
Ninety-four outpatient psoriasis patients and 51 healthy people were included in the study.
Patients having systemic hypertension, diabetes mellitus, history of ischemic heart disease,
significant valvular heart disease, chronic obstructive pulmonary disease, hypo or
hyper-thyroidism, renal failure or any associated systemic disease were excluded. Diagnosis
of psoriasis was confirmed by dermatological examination and/or punch biopsy. Severity of
the psoriasis was evaluated by psoriasis area and severity index (PASI). Patients were
evaluated by physical examination, 12-lead electrocardiography and transthoracic
echocardiography.
